Reverie Labs acquires Ginkgo Bioworks

Deal terms as reported in the coverage below.

Decision brief

What changed

Reverie Labs, a machine-learning-driven small-molecule drug discovery startup co-founded by Ankit Gupta in YC's Winter 2018 batch, was acquired by Ginkgo Bioworks in 2024; Gupta has since joined Y Combinator as a General Partner.

Why it matters

This signals continued consolidation of AI-driven drug discovery capabilities into larger synthetic biology platforms like Ginkgo Bioworks, which could affect competitive dynamics for pharma R&D partnerships and biotech M&A pricing. It also reflects a talent flow pattern where successful applied-ML founders move into venture capital, potentially shaping which AI biotech startups get funded next.

Affected roles

CEO CTO

Evidence

The only source is a Y Combinator blog post announcing Gupta's new GP role, which mentions the Ginkgo acquisition as background context rather than as primary reporting; no independent financial press, SEC filing, or Ginkgo press release is cited to corroborate deal terms or scale.

What remains uncertain

Deal size, valuation, strategic rationale, integration outcomes, and whether Reverie's ML models remain active within Ginkgo's platform are all unconfirmed; the acquisition is mentioned only as biographical context in a hiring announcement, not verified through primary deal disclosures.

Monitor next

Watch for any official Ginkgo Bioworks disclosure, SEC filing, or pharma partnership announcement referencing Reverie Labs' ML technology to confirm deal terms and integration status.

Analytical support, not advice — assumptions and open questions stated above.

Source coverage